- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07950592
The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)
At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy
Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.
A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:
- Get personalized resources that can help them navigate through the stages of their treatment.
- Access vetted information about their cancer & treatment from a health library.
- Receive surveys about their health and well-being.
- Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
- Connect with a physiotherapist to discuss healthy living and wellness.
Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.
At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Tulin Cil
- Номер телефона: 3984 416-946-4507
- Электронная почта: tulin.cil@uhn.ca
Учебное резервное копирование контактов
- Имя: Emma Reel
- Номер телефона: 647-202-1028
- Электронная почта: emma.reel@uhn.ca
Места учебы
-
-
Ontario
-
Toronto, Ontario, Канада, M5G2M9
- University Health Network
-
Контакт:
- Tulin Cil, MD, MEd
- Номер телефона: 4169464507
- Электронная почта: tulin.cil@uhn.ca
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Females (assigned female at birth)*
- Diagnosed with primary invasive BC and receiving curative intent treatment
- Must have neoadjuvant chemotherapy as their first step in treatment
- Receiving systemic therapy at UHN
- Age≥18
- Access to an electronic device with connection to the internet
- A valid email address
- Can communicate in English
Exclusion Criteria:
- Males (assigned male at birth), as BC surgical treatment options and experiences are different
- Diagnosed with non-operable breast cancer
- Stage 4/metastatic (whether determined at diagnosis or during surgery)
- Those with hearing or visual challenges
- Should not be enrolled in any other UHN study using an e-Health application
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Без вмешательства: Control
Standard care |
|
|
Экспериментальный: Intervention (App)
App + standard care |
The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Patient Activation Measure 13 (PAM-13)
Временное ограничение: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Impact of Events Scale - Revised (IES-R)
Временное ограничение: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Generalized Anxiety Disorder 7 (GAD-7)
Временное ограничение: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
Временное ограничение: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales). |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
Временное ограничение: 9 months post-baseline
|
A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information. |
9 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
Временное ограничение: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 42-item survey assessing quality of life specifically for breast cancer patients. The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Health Education Impact Questionnaire (heiQ)
Временное ограничение: Baseline 9 months post-baseline
|
A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome. |
Baseline 9 months post-baseline
|
|
Clinical Evaluation Questionnaire -INS (CEQ-INS)
Временное ограничение: 9 months post-baseline
|
A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team. |
9 months post-baseline
|
|
Health Service Outcomes - Wait Times
Временное ограничение: Until 15 months post-baseline
|
The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals. |
Until 15 months post-baseline
|
|
Health Service Outcomes - Ambulatory Clinical Activity
Временное ограничение: Until 15 months post-baseline
|
Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS). |
Until 15 months post-baseline
|
|
Health Service Outcomes - Discharge Information
Временное ограничение: Until 15 months post-baseline
|
Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery. |
Until 15 months post-baseline
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 24-5369
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .